NEW YORK, April 5, 2012 /PRNewswire/ -- Bernstein Liebhard LLP is investigating whether the Board of Directors of Allos Therapeutics,

BOSTON, April 5, 2012 /PRNewswire/ -- Block & Leviton LLP, a Boston based law firm representing investors nationwide, is investigating possible breaches of fiduciary duties by the Board

MINNETONKA, Minn., Feb.

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors.

Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported results for the third quarter of 2008. For the three months ended September 30, 2008, the Company reported a net loss of $13.2 million, or ($0.16) per share.